The main objective of this study is to collect data on the long-term safety of azer-cel, primarily through the capture of clinical events of interest (CEI) for up to 15 years following participation in TG-Azercel -101 study.
Study Type
OBSERVATIONAL
Enrollment
32
No Intervention
Number of Participants With Clinically Significant CEI
Time frame: Up to 15 years
Number of Participants With Clinically Significant CEI Based on Severity
Time frame: Up to 15 years
Duration of Clinically Significant CEI
Time frame: Up to 15 years
Time to Onset of Clinically Significant CEI
Time frame: Up to 15 years
Number of Participants With CEI and all Serious Adverse Events (SAEs)
Time frame: Up to 15 years
Duration of Disease Response Measured by Expanded Disability Status Scale (EDSS) Scores
The EDSS is a standardized tool used to measure disability in participants with multiple sclerosis (MS). The EDSS scores range from 0 to 10, based on the severity of disability. Higher score indicates severity of disability.
Time frame: Up to 15 years
Duration of Disease Response Measured by Number of MS Relapses
Time frame: Up to 15 years
Duration of Disease Response Based on Number of T2 Lesions and Gd-enhancing T1 Lesions
Time frame: Up to 15 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.